The COVID-19 pandemic transformed an unfamiliar respiratory infection into one of the most intensively studied diseases in modern history. Although fever, cough, fatigue, and loss of smell quickly became recognized symptoms, doctors also began reporting unusual skin changes. Among the most distinctive were red or purple swellings on the toes—and occasionally the fingers—resembling chilblains caused by exposure to cold. Popularly called “COVID toes,” these lesions attracted attention because they frequently appeared in children and young adults who otherwise felt well and often tested negative for active infection. COVID toes illustrate both the wide-ranging effects of SARS-CoV-2 and the difficulty of proving that a striking clinical pattern has a single cause.
COVID toes are medically described as chilblain-like lesions or pernio-like eruptions. They most commonly affect the tips and upper surfaces of the toes but may also develop along the sides of the feet, on the soles, or on the fingers. Affected areas can become red, pink, or violet and may swell or form raised spots. Some people experience itching, tenderness, burning, or pain, while others notice only a change in appearance. Blisters, small areas of tissue damage, or crusting can occasionally occur. Unlike traditional chilblains, which usually develop after exposure to cold and damp conditions, many pandemic-era cases appeared during warm weather or in people without a history of similar problems.
Reports increased sharply during the first months of the pandemic. Dermatologists in Europe and North America described clusters of young patients with chilblain-like lesions at a time when community transmission of COVID-19 was high. The timing suggested an association with SARS-CoV-2, but an unusual pattern complicated the evidence: many affected people had negative polymerase chain reaction tests and no detectable antibodies. Some had experienced mild respiratory symptoms or contact with an infected person several weeks earlier, whereas others had no known exposure. Consequently, COVID toes became a plausible but sometimes controversial manifestation of infection rather than a simple diagnostic sign.
Several explanations have been proposed. One leading theory involves the body’s interferon response. Interferons are proteins that help cells limit viral replication. Children and younger adults may sometimes produce a rapid and powerful type I interferon response that controls SARS-CoV-2 before it causes severe illness or generates easily measurable antibody levels. That same response may promote inflammation around small blood vessels in the skin, producing chilblain-like lesions. Under this interpretation, COVID toes could be evidence of an effective antiviral defence accompanied by localized inflammation.
Other proposed mechanisms include injury to the lining of small blood vessels, activation of the immune system, and microscopic changes in circulation. SARS-CoV-2 can provoke vascular and inflammatory abnormalities, especially in severe disease, but COVID toes generally occur in people with mild or absent systemic symptoms. The lesions should therefore not automatically be equated with the dangerous blood clots associated with serious COVID-19. Some biopsy studies have found inflammation around small vessels and other changes consistent with chilblains, yet these findings do not by themselves prove that the virus directly invaded the skin.
Researchers have also considered the indirect effects of pandemic life. Lockdowns changed footwear, exercise, heating, stress levels, and exposure to cold floors. People spent more time at home, sometimes barefoot, while heightened awareness encouraged them to seek medical advice for marks that might previously have gone unnoticed. Studies comparing case numbers with infection rates have produced mixed conclusions. In some settings, chilblain-like eruptions rose alongside COVID-19 waves; in others, tests and epidemiological evidence did not support a direct link. It is possible that the label “COVID toes” includes several conditions that look alike but arise through different pathways.
Diagnosis is usually clinical. A healthcare professional examines the lesions and asks about their duration, possible cold exposure, medications, previous chilblains, COVID-19 symptoms, and contact with infected individuals. Depending on the circumstances, testing for active or past SARS-CoV-2 infection may be appropriate, although a negative result does not necessarily settle the question. Doctors may investigate alternative causes when lesions are severe, recurrent, unusually persistent, or accompanied by other symptoms. Conditions such as autoimmune disease, circulation disorders, vasculitis, pressure injuries, and ordinary cold-induced chilblains can resemble COVID toes. Rarely, a skin biopsy or blood tests may be needed.
For most patients, the outlook is reassuring. Lesions commonly resolve without treatment within several weeks, although some persist longer or recur. Keeping the feet comfortably warm and dry, avoiding tight footwear, and resisting scratching can reduce irritation. Moisturizers may protect damaged skin, while a clinician may recommend a topical corticosteroid for significant itching or inflammation. Pain relief can be used when appropriate. Antibiotics do not treat the lesions unless a separate bacterial infection develops, and blood-thinning medication should not be taken merely because the term COVID toes suggests a circulation problem.
Certain warning signs deserve prompt medical attention. These include severe or rapidly increasing pain, spreading redness, pus, fever, blackened skin, numbness, an open wound, or evidence that circulation is impaired. People with diabetes, known vascular disease, immune suppression, or other serious medical conditions should seek advice early. Emergency care is warranted for major COVID-19 symptoms such as difficulty breathing, persistent chest pain, confusion, or bluish discolouration of the face or lips. A person who may be infectious should also follow current public-health guidance concerning testing and contact with others.
The scientific significance of COVID toes extends beyond dermatology. Their emergence demonstrated how networks of clinicians and patients can quickly identify possible manifestations of a new disease. It also showed the limits of observation during a crisis. A sudden rise in reports can reveal a genuine biological phenomenon, but changes in behaviour, awareness, testing, and healthcare access can influence what is counted. Establishing causation requires consistent laboratory, pathological, and epidemiological evidence, not merely a memorable name.
In conclusion, COVID toes are chilblain-like lesions that became widely recognized during the pandemic, especially among younger people with mild or no other symptoms. A strong interferon response and inflammation of small blood vessels offer biologically credible explanations, yet negative tests and competing environmental factors leave important questions unresolved. Most cases are temporary and benign, but careful assessment is valuable when symptoms are severe or atypical. COVID toes remain a useful lesson in medical uncertainty: visible on the skin, scientifically intriguing, and best understood through balanced attention to both emerging evidence and alternative explanations.
Selected References
- Freeman, E. E., et al. “Pernio-like skin lesions associated with COVID-19: A case series of 318 patients from 8 countries.” Journal of the American Academy of Dermatology, 2020.
- Hubiche, T., et al. “Clinical, laboratory, and interferon-alpha response characteristics of patients with chilblain-like lesions during the COVID-19 pandemic.” JAMA Dermatology, 2021.
- American Academy of Dermatology Association. “COVID toes and other rashes COVID-19 may cause.”
- DermNet. “COVID toes and other skin manifestations of COVID-19.”